These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 13484272)

  • 1. [Reduction of carcinostatic action of dopan by its structural analogues].
    PLATONOVA GN
    Patol Fiziol Eksp Ter; 1957; 1(3):22-8. PubMed ID: 13484272
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopan.
    WHITE FR
    Cancer Chemother Rep; 1961 Oct; 14():169-73. PubMed ID: 14006515
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization studies on the carcinostatic activity of 5-diazouracil.
    SASSENRATH EN; KELLS AM; GREENBERG DM
    Cancer Res; 1959 Apr; 19(3 Pt 1):259-67. PubMed ID: 13638968
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopan and related compounds.
    LARIONOV L
    Cancer Chemother Rep; 1961 Jun; 12():205-6. PubMed ID: 13759106
    [No Abstract]   [Full Text] [Related]  

  • 5. Further clinical studies with 5-fluorouracil.
    ANSFIELD FJ; CURRERI AR
    J Natl Cancer Inst; 1959 Mar; 22(3):497-507. PubMed ID: 13642014
    [No Abstract]   [Full Text] [Related]  

  • 6. [Derivatives of 3,5-dihydroxy-1,2,4-triazines (6-azauracil) with apparent cytostatic action].
    CRISTESCU C; MARCUS J
    Pharmazie; 1961 Mar; 16():135-7. PubMed ID: 13696490
    [No Abstract]   [Full Text] [Related]  

  • 7. [Result of use of dopan in treatment of chronic myeloleukosis].
    MOKEEVA RA
    Sov Med; 1958 Sep; 22(9):42-6. PubMed ID: 13615483
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the carcinostatic activity in mice of 6-azauracil riboside (azauridine), in comparison with that of 6-azauracil.
    JAFFE JJ; HANDSCHUMACHER RE; WELCH AD
    Yale J Biol Med; 1957 Dec; 30(3):168-75. PubMed ID: 13507398
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancement of carcinostatic activity of omega-hydroxy fatty acids by their esterification through increased uptake into tumor cells.
    Kusumoto K; Kageyama K; Tanaka H; Kogawa H; Miwa N
    Oncol Rep; 2004 Apr; 11(4):857-61. PubMed ID: 15010885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the surprising metal-ion-binding properties of 5- and 6-uracilmethylphosphonate (5Umpa2- and 6Umpa2-) in aqueous solution and crystal structures of the dimethyl and di(isopropyl) esters of H2(6Umpa).
    Freisinger E; Griesser R; Lippert B; Moreno-Luque CF; Niclós-Gutiérrez J; Ochocki J; Operschall BP; Sigel H
    Chemistry; 2008; 14(32):10036-46. PubMed ID: 18803205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turnover of thymidine in the DNA of marrow and intestinal mucosa in mice, and its response to administration of 5-fluorouracil.
    FIELD EO; KRISS JP; TUNG LA
    Cancer Res; 1961 Jan; 21():2-8. PubMed ID: 13699353
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-tumor and anti-invasive effects of diverse delta-alkyllactones: dependence on molecular side-chain length, action period and intracellular uptake.
    Tanaka H; Kageyama K; Yoshimura N; Asada R; Kusumoto K; Miwa N
    Life Sci; 2007 Apr; 80(20):1851-5. PubMed ID: 17382354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells.
    Marchal JA; Núñez MC; Suárez I; Díaz-Gavilán M; Gómez-Vidal JA; Boulaiz H; Rodríguez-Serrano F; Gallo MA; Espinosa A; Aránega A; Campos JM
    Breast Cancer Res Treat; 2007 Nov; 105(3):237-46. PubMed ID: 17124554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Our first clinical experiences with azauracil].
    MODR Z; SMAHEL O; SVEHLA C
    Cas Lek Cesk; 1959 Jul; 98(28):873-4. PubMed ID: 13671489
    [No Abstract]   [Full Text] [Related]  

  • 15. [Azauracil in the treatment of lymphogranuloma].
    KONIG J
    Cas Lek Cesk; 1959 Jul; 98(28):875-6. PubMed ID: 13671490
    [No Abstract]   [Full Text] [Related]  

  • 16. [The carcinostatic mechanism of action of ethyleneimino compounds].
    HOLZER H; KROGER H
    Biochem Z; 1958; 330(7):579-90. PubMed ID: 13618247
    [No Abstract]   [Full Text] [Related]  

  • 17. Carcinostatic action of polycarbonyl compounds and their derivatives. I. 3-Ethoxy-2-ketobutyraldehyde and related compounds.
    FRENCH FA; FREEDLANDER BL
    Cancer Res; 1958 Feb; 18(2):172-5. PubMed ID: 13511372
    [No Abstract]   [Full Text] [Related]  

  • 18. Further experiments on the carcinostatic action of bis (2-hydroxy-3,5-dibromophenylazo)-propylphloroglucinol.
    KOSHIMURA S; HIRATA R; MURASAWA K; BANDO Y; MASUSAKI T; OHTA T; ISHIKAWA M
    Gan; 1957 Dec; 48(4):439-40. PubMed ID: 13524443
    [No Abstract]   [Full Text] [Related]  

  • 19. Further experiments on the carcinostatic action of bis(2-hydroxy-3,5-dibromophenylazo)-N-propylphloroglucinol.
    KOSHIMURA S; MURASAWA K; HIRATA R; BANDO Y
    Acta Unio Int Contra Cancrum; 1959; 15(Suppl 1)():154-8. PubMed ID: 14411188
    [No Abstract]   [Full Text] [Related]  

  • 20. On the relation between the electronic structure and anti-tumor activity of carcinostatic compounds.
    FUKUI K; NAGATA C; YONEZAWA T; MOROKUMA K; IMAMURA A
    Gan; 1961 Mar; 52():1-14. PubMed ID: 13702520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.